{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T06:42:07Z","timestamp":1794465727631,"version":"4.9.1"},"reference-count":141,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T00:00:00Z","timestamp":1714003200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.heliyon.2024.e30387","type":"journal-article","created":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T12:26:10Z","timestamp":1714047970000},"page":"e30387","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"title":["From NAFLD to NASH: Understanding the spectrum of non-alcoholic liver diseases and their consequences"],"prefix":"10.1016","volume":"10","author":[{"given":"Ahmed M.","family":"Samy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed A.","family":"Kandeil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina","family":"Sabry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.A.","family":"Abdel-Ghany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed O.","family":"Mahmoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.heliyon.2024.e30387_bib1","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.cmet.2017.08.002","article-title":"Nonalcoholic fatty liver disease as a nexus of metabolic and hepatic diseases","volume":"27","author":"Samuel","year":"2018","journal-title":"Cell Metab."},{"key":"10.1016\/j.heliyon.2024.e30387_bib2","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.heliyon.2024.e30387_bib3","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1002\/hep.29085","article-title":"Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta\u2010analysis","volume":"65","author":"Dulai","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.heliyon.2024.e30387_bib4","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.jhep.2018.10.033","article-title":"Non-alcoholic fatty liver disease\u2013a global public health perspective","volume":"70","author":"Younossi","year":"2019","journal-title":"J. Hepatol."},{"key":"10.1016\/j.heliyon.2024.e30387_bib5","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/hep.29466","article-title":"Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease","volume":"67","author":"Estes","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.heliyon.2024.e30387_bib6","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.cell.2021.04.015","article-title":"Mechanisms and disease consequences of nonalcoholic fatty liver disease","volume":"184","author":"Loomba","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.heliyon.2024.e30387_bib7","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1186\/s13098-022-00930-w","article-title":"Age patterns of nonalcoholic fatty liver disease incidence: heterogeneous associations with metabolic changes","volume":"14","author":"Lin","year":"2022","journal-title":"Diabetol. Metab. Syndr."},{"key":"10.1016\/j.heliyon.2024.e30387_bib8","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.5005\/jp-journals-10018-1370","article-title":"Gender differences in nonalcoholic fatty liver Disease","volume":"12","author":"Nagral","year":"2022","journal-title":"Euroasian J. Hepato-Gastroenterology"},{"key":"10.1016\/j.heliyon.2024.e30387_bib9","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1002\/hep.30626","article-title":"Sex differences in nonalcoholic fatty liver disease: state of the art and identification of research gaps","volume":"70","author":"Lonardo","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.heliyon.2024.e30387_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13293-022-00475-7","article-title":"Sex and age differences in the association of fatty liver index-defined non-alcoholic fatty liver disease with cardiometabolic risk factors: a cross-sectional study","volume":"13","author":"Fresneda","year":"2022","journal-title":"Biol. Sex Differ."},{"key":"10.1016\/j.heliyon.2024.e30387_bib11","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.cgh.2017.09.041","article-title":"Racial and ethnic disparities in nonalcoholic fatty liver disease prevalence, severity, and outcomes in the United States: a systematic review and meta-analysis","volume":"16","author":"Rich","year":"2018","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.heliyon.2024.e30387_bib12","doi-asserted-by":"crossref","first-page":"4556","DOI":"10.3390\/nu14214556","article-title":"Race and ethnicity in non-alcoholic fatty liver disease (nafld): a narrative review","volume":"14","author":"Riazi","year":"2022","journal-title":"Nutrients"},{"key":"10.1016\/j.heliyon.2024.e30387_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2023.1076730","article-title":"Racial\/ethnic and gender disparity in the severity of NAFLD among people with diabetes or prediabetes","volume":"14","author":"Shaheen","year":"2023","journal-title":"Front. Physiol."},{"key":"10.1016\/j.heliyon.2024.e30387_bib14","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.3350\/cmh.2022.0365","article-title":"Global incidence and prevalence of nonalcoholic fatty liver disease","volume":"29","author":"Teng","year":"2023","journal-title":"Clin. Mol. Hepatol."},{"key":"10.1016\/j.heliyon.2024.e30387_bib15","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e30387_bib16","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.jhep.2023.04.036","article-title":"Changing epidemiology, global trends and implications for outcomes of NAFLD","volume":"79","author":"Wong","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.heliyon.2024.e30387_bib17","doi-asserted-by":"crossref","first-page":"206","DOI":"10.5009\/gnl20127","article-title":"Recent epidemiology of nonalcoholic fatty liver disease","volume":"15","author":"Murag","year":"2021","journal-title":"Gut Liver"},{"key":"10.1016\/j.heliyon.2024.e30387_bib18","doi-asserted-by":"crossref","first-page":"8263","DOI":"10.3748\/wjg.v23.i47.8263","article-title":"Clinical epidemiology and disease burden of nonalcoholic fatty liver disease","volume":"23","author":"Perumpail","year":"2017","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.heliyon.2024.e30387_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12916-018-1103-x","article-title":"Real-world data reveal a diagnostic gap in non-alcoholic fatty liver disease","volume":"16","author":"Alexander","year":"2018","journal-title":"BMC Med."},{"key":"10.1016\/j.heliyon.2024.e30387_bib20","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1002\/hep.30946","article-title":"The 20% rule of NASH progression: the natural history of advanced fibrosis and cirrhosis caused by NASH","volume":"70","author":"Loomba","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.heliyon.2024.e30387_bib21","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1002\/hep.31113","article-title":"PNPLA3 genotype and risk of liver and all-cause mortality","volume":"71","author":"Stender","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.heliyon.2024.e30387_bib22","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.cgh.2014.04.014","article-title":"Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies","volume":"13","author":"Singh","year":"2015","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.heliyon.2024.e30387_bib23","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1053\/j.gastro.2005.04.014","article-title":"The natural history of nonalcoholic fatty liver disease: a population-based cohort study","volume":"129","author":"Adams","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.heliyon.2024.e30387_bib24","article-title":"Nonoverweight nonalcoholic fatty liver disease and incident cardiovascular disease: a post hoc analysis of a cohort study","volume":"96","author":"Yoshitaka","year":"2017","journal-title":"Medicine (Baltim.)"},{"key":"10.1016\/j.heliyon.2024.e30387_bib25","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1002\/hep.30251","article-title":"Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"69","author":"Younossi","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.heliyon.2024.e30387_bib26","article-title":"A multi-society Delphi consensus statement on new fatty liver disease nomenclature","author":"Rinella","year":"2023","journal-title":"Ann. Hepatol."},{"key":"10.1016\/j.heliyon.2024.e30387_bib27","article-title":"Nonalcoholic fatty liver disease is associated with excessive calorie intake rather than a distinctive dietary pattern","volume":"95","author":"Wehmeyer","year":"2016","journal-title":"Medicine (Baltim.)"},{"key":"10.1016\/j.heliyon.2024.e30387_bib28","first-page":"719","article-title":"The sweet path to metabolic demise: fructose and lipid synthesis, Trends Endocrinol","volume":"27","author":"Herman","year":"2016","journal-title":"Metab."},{"key":"10.1016\/j.heliyon.2024.e30387_bib29","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1152\/physrev.00063.2017","article-title":"Mechanisms of insulin action and insulin resistance","volume":"98","author":"Petersen","year":"2018","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.heliyon.2024.e30387_bib30","doi-asserted-by":"crossref","first-page":"10455","DOI":"10.1074\/jbc.M117.786525","article-title":"Lack of liver glycogen causes hepatic insulin resistance and steatosis in mice","volume":"292","author":"Irimia","year":"2017","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.heliyon.2024.e30387_bib31","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/ng.3714","article-title":"Integrative genomic analysis implicates limited peripheral adipose storage capacity in the pathogenesis of human insulin resistance","volume":"49","author":"Lotta","year":"2017","journal-title":"Nat. Genet."},{"key":"10.1016\/j.heliyon.2024.e30387_bib32","doi-asserted-by":"crossref","first-page":"E11285","DOI":"10.1073\/pnas.1716990115","article-title":"Mechanism by which arylamine N-acetyltransferase 1 ablation causes insulin resistance in mice","volume":"114","author":"Camporez","year":"2017","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.heliyon.2024.e30387_bib33","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1038\/ijo.2017.4","article-title":"What have human experimental overfeeding studies taught us about adipose tissue expansion and susceptibility to obesity and metabolic complications?","volume":"41","author":"Cuthbertson","year":"2017","journal-title":"Int. J. Obes."},{"key":"10.1016\/j.heliyon.2024.e30387_bib34","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ccr.2007.05.008","article-title":"Defining the role of mTOR in cancer","volume":"12","author":"Guertin","year":"2007","journal-title":"Cancer Cell"},{"key":"10.1016\/j.heliyon.2024.e30387_bib35","doi-asserted-by":"crossref","first-page":"8166","DOI":"10.1073\/pnas.1921694117","article-title":"Metabolic control analysis of hepatic glycogen synthesis in vivo","volume":"117","author":"Nozaki","year":"2020","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.heliyon.2024.e30387_bib36","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/nm.3579","article-title":"Leptin reverses diabetes by suppression of the hypothalamic-pituitary-adrenal axis","volume":"20","author":"Perry","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.heliyon.2024.e30387_bib37","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.cell.2015.01.012","article-title":"Hepatic acetyl CoA links adipose tissue inflammation to hepatic insulin resistance and type 2 diabetes","volume":"160","author":"Perry","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.heliyon.2024.e30387_bib38","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1073\/pnas.0914798107","article-title":"Bifurcation of insulin signaling pathway in rat liver: mTORC1 required for stimulation of lipogenesis, but not inhibition of gluconeogenesis","volume":"107","author":"Li","year":"2010","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.heliyon.2024.e30387_bib39","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1056\/NEJMoa0907295","article-title":"Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease","volume":"362","author":"Petersen","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.heliyon.2024.e30387_bib40","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1073\/pnas.1423952112","article-title":"Insulin-independent regulation of hepatic triglyceride synthesis by fatty acids","volume":"112","author":"Vatner","year":"2015","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.heliyon.2024.e30387_bib41","doi-asserted-by":"crossref","first-page":"489","DOI":"10.2337\/dc20-1644","article-title":"Hepatic insulin resistance is not pathway selective in humans with nonalcoholic fatty liver disease","volume":"44","author":"Ter Horst","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.heliyon.2024.e30387_bib42","first-page":"1","article-title":"Physiological and pathological roles of lipogenesis","author":"Jeon","year":"2023","journal-title":"Nat. Metab."},{"key":"10.1016\/j.heliyon.2024.e30387_bib43","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.2337\/db21-0649","article-title":"Hepatic GSK3\u03b2-dependent CRY1 degradation contributes to diabetic hyperglycemia","volume":"71","author":"Kim","year":"2022","journal-title":"Diabetes"},{"key":"10.1016\/j.heliyon.2024.e30387_bib44","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1146\/annurev-nutr-071714-034355","article-title":"The roles of mTOR complexes in lipid metabolism","volume":"35","author":"Caron","year":"2015","journal-title":"Annu. Rev. Nutr."},{"key":"10.1016\/j.heliyon.2024.e30387_bib45","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1038\/s42255-023-00843-6","article-title":"Liver insulinization as a driver of triglyceride dysmetabolism","volume":"5","author":"Cook","year":"2023","journal-title":"Nat. Metab."},{"key":"10.1016\/j.heliyon.2024.e30387_bib46","series-title":"Semin. Liver Dis.","first-page":"124","article-title":"Genetics of nonalcoholic fatty liver disease: from pathogenesis to therapeutics","author":"Sookoian","year":"2019"},{"key":"10.1016\/j.heliyon.2024.e30387_bib47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-019-09455-9","article-title":"A gut microbiome signature for cirrhosis due to nonalcoholic fatty liver disease","volume":"10","author":"Caussy","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.heliyon.2024.e30387_bib48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11892-019-1151-4","article-title":"Epigenetic markers and microbiota\/metabolite-induced epigenetic modifications in the pathogenesis of obesity, metabolic syndrome, type 2 diabetes, and non-alcoholic fatty liver disease","volume":"19","author":"Stols-Gon\u00e7alves","year":"2019","journal-title":"Curr. Diab. Rep."},{"key":"10.1016\/j.heliyon.2024.e30387_bib49","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1136\/gutjnl-2015-309456","article-title":"Serum microRNAs explain discordance of non-alcoholic fatty liver disease in monozygotic and dizygotic twins: a prospective study","volume":"65","author":"Zarrinpar","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.heliyon.2024.e30387_bib50","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/hepr.13330","article-title":"Inhibition of microRNA\u2010124a attenuates non\u2010alcoholic fatty liver disease through upregulation of adipose triglyceride lipase and the effect of liraglutide intervention","volume":"49","author":"Fang","year":"2019","journal-title":"Hepatol. Res."},{"key":"10.1016\/j.heliyon.2024.e30387_bib51","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nrgastro.2016.160","article-title":"Developmental origins of NAFLD: a womb with a clue","volume":"14","author":"Wesolowski","year":"2017","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.heliyon.2024.e30387_bib52","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0021662","article-title":"Offspring of mothers fed a high fat diet display hepatic cell cycle inhibition and associated changes in gene expression and DNA methylation","volume":"6","author":"Dudley","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.heliyon.2024.e30387_bib53","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.cmet.2020.06.005","article-title":"A universal gut-microbiome-derived signature predicts cirrhosis","volume":"32","author":"Oh","year":"2020","journal-title":"Cell Metab."},{"key":"10.1016\/j.heliyon.2024.e30387_bib54","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1038\/s41591-018-0061-3","article-title":"Molecular phenomics and metagenomics of hepatic steatosis in non-diabetic obese women","volume":"24","author":"Hoyles","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.heliyon.2024.e30387_bib55","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1002\/hep.28356","article-title":"The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota","volume":"63","author":"Boursier","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.heliyon.2024.e30387_bib56","doi-asserted-by":"crossref","first-page":"5340","DOI":"10.3390\/nu14245340","article-title":"Clearing steatosis prior to liver surgery for colorectal metastasis: a narrative review and case illustration","volume":"14","author":"Peloso","year":"2022","journal-title":"Nutrients"},{"key":"10.1016\/j.heliyon.2024.e30387_bib57","doi-asserted-by":"crossref","first-page":"238","DOI":"10.3390\/metabo12030238","article-title":"Emerging role of nuclear receptors for the treatment of NAFLD and NASH","volume":"12","author":"Welch","year":"2022","journal-title":"Metabolites"},{"key":"10.1016\/j.heliyon.2024.e30387_bib58","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/hep.28709","article-title":"Bile acids and nonalcoholic fatty liver disease: molecular insights and therapeutic perspectives","volume":"65","author":"Arab","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.heliyon.2024.e30387_bib59","series-title":"Semin. Immunopathol.","first-page":"547","article-title":"Bile acids and their receptors: modulators and therapeutic targets in liver inflammation","author":"Bertolini","year":"2022"},{"key":"10.1016\/j.heliyon.2024.e30387_bib60","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/s41575-021-00566-7","article-title":"Role of bile acids and their receptors in gastrointestinal and hepatic pathophysiology","volume":"19","author":"Fuchs","year":"2022","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.heliyon.2024.e30387_bib61","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1053\/j.gastro.2017.01.055","article-title":"Bile acid control of metabolism and inflammation in obesity, type 2 diabetes, dyslipidemia, and nonalcoholic fatty liver disease","volume":"152","author":"Ch\u00e1vez-Talavera","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.heliyon.2024.e30387_bib62","first-page":"E399","article-title":"Obeticholic acid ameliorates dyslipidemia but not glucose tolerance in mouse model of gestational diabetes","volume":"317","author":"McIlvride","year":"2019","journal-title":"Am. J. Physiol. Metab."},{"key":"10.1016\/j.heliyon.2024.e30387_bib63","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1002\/jcb.27635","article-title":"Interaction of gut microbiota with dysregulation of bile acids in the pathogenesis of nonalcoholic fatty liver disease and potential therapeutic implications of probiotics","volume":"120","author":"Chen","year":"2019","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.heliyon.2024.e30387_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101119","article-title":"Nuclear receptors and transcriptional regulation in non-alcoholic fatty liver disease","volume":"50","author":"Xiao","year":"2021","journal-title":"Mol. Metab."},{"key":"10.1016\/j.heliyon.2024.e30387_bib65","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13287-022-02929-6","article-title":"The role of the immune system in the pathogenesis of NAFLD and potential therapeutic impacts of mesenchymal stem cell-derived extracellular vesicles","volume":"13","author":"Moayedfard","year":"2022","journal-title":"Stem Cell Res. Ther."},{"key":"10.1016\/j.heliyon.2024.e30387_bib66","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.molmed.2018.03.005","article-title":"IL-1 family cytokine pathways underlying NAFLD: towards new treatment strategies","volume":"24","author":"Mirea","year":"2018","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.heliyon.2024.e30387_bib67","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.jhep.2017.01.022","article-title":"NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice","volume":"66","author":"Mridha","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.heliyon.2024.e30387_bib68","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.jhep.2017.11.040","article-title":"Gasdermin D plays a key role as a pyroptosis executor of non-alcoholic steatohepatitis in humans and mice","volume":"68","author":"Xu","year":"2018","journal-title":"J. Hepatol."},{"key":"10.1016\/j.heliyon.2024.e30387_bib69","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/nri.2017.11","article-title":"Liver macrophages in tissue homeostasis and disease","volume":"17","author":"Krenkel","year":"2017","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.heliyon.2024.e30387_bib70","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.molcel.2019.07.028","article-title":"Landscape of intercellular crosstalk in healthy and NASH liver revealed by single-cell secretome gene analysis","volume":"75","author":"Xiong","year":"2019","journal-title":"Mol. Cell."},{"key":"10.1016\/j.heliyon.2024.e30387_bib71","doi-asserted-by":"crossref","first-page":"97","DOI":"10.4049\/jimmunol.1501175","article-title":"Progression from nonalcoholic fatty liver to nonalcoholic steatohepatitis is marked by a higher frequency of Th17 cells in the liver and an increased Th17\/resting regulatory T cell ratio in peripheral blood and in the liver","volume":"196","author":"Rau","year":"2016","journal-title":"J. Immunol."},{"key":"10.1016\/j.heliyon.2024.e30387_bib72","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.tips.2018.01.003","article-title":"Specialized proresolving mediators: enhancing nonalcoholic steatohepatitis and fibrosis resolution","volume":"39","author":"Musso","year":"2018","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.heliyon.2024.e30387_bib73","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/s41575-018-0009-6","article-title":"Triggering and resolution of inflammation in NASH","volume":"15","author":"Schuster","year":"2018","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.heliyon.2024.e30387_bib74","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.751802","article-title":"Role of neutrophils in the pathogenesis of nonalcoholic steatohepatitis","volume":"12","author":"Hwang","year":"2021","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.heliyon.2024.e30387_bib75","doi-asserted-by":"crossref","first-page":"536","DOI":"10.15252\/embj.201591857","article-title":"p38\u03b3 and p38\u03b4 reprogram liver metabolism by modulating neutrophil infiltration","volume":"35","author":"Gonz\u00e1lez\u2010Ter\u00e1n","year":"2016","journal-title":"EMBO J."},{"key":"10.1016\/j.heliyon.2024.e30387_bib76","doi-asserted-by":"crossref","first-page":"4091","DOI":"10.1172\/JCI122258","article-title":"Neutrophils contribute to spontaneous resolution of liver inflammation and fibrosis via microRNA-223","volume":"129","author":"Calvente","year":"2019","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.heliyon.2024.e30387_bib77","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/j.jhep.2022.06.004","article-title":"Soluble TREM2 levels reflect the recruitment and expansion of TREM2+ macrophages that localize to fibrotic areas and limit NASH","volume":"77","author":"Hendrikx","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.heliyon.2024.e30387_bib78","doi-asserted-by":"crossref","first-page":"341","DOI":"10.3390\/cells12030341","article-title":"TREM2 regulates the removal of apoptotic cells and inflammatory processes during the progression of NAFLD","volume":"12","author":"Liebold","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.heliyon.2024.e30387_bib79","doi-asserted-by":"crossref","DOI":"10.1172\/JCI135197","article-title":"TREM2 sustains macrophage-hepatocyte metabolic coordination in nonalcoholic fatty liver disease and sepsis","volume":"131","author":"Hou","year":"2021","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.heliyon.2024.e30387_bib80","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41575-019-0210-2","article-title":"Adaptive immunity: an emerging player in the progression of NAFLD","volume":"17","author":"Sutti","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.heliyon.2024.e30387_bib81","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1002\/hep.31889","article-title":"The emerging role of B cells in the pathogenesis of NAFLD","volume":"74","author":"Barrow","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.heliyon.2024.e30387_bib82","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232012376","article-title":"Role of B lymphocytes in the pathogenesis of NAFLD: a 2022 update","volume":"23","author":"Deng","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.heliyon.2024.e30387_bib83","doi-asserted-by":"crossref","first-page":"4831","DOI":"10.3748\/wjg.v29.i32.4831","article-title":"Non-alcoholic fatty liver disease: immunological mechanisms and current treatments","volume":"29","author":"Petagine","year":"2023","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.heliyon.2024.e30387_bib84","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.760860","article-title":"Emerging roles of T cells in the pathogenesis of nonalcoholic steatohepatitis and hepatocellular carcinoma","volume":"12","author":"Hirsova","year":"2021","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.heliyon.2024.e30387_bib85","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/s41586-021-03233-8","article-title":"Auto-aggressive CXCR6+ CD8 T cells cause liver immune pathology in NASH","volume":"592","author":"Dudek","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.heliyon.2024.e30387_bib86","article-title":"Tissue-resident memory T cells in chronic liver diseases: phenotype, development and function","volume":"13","author":"Li","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.heliyon.2024.e30387_bib87","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-020-16092-0","article-title":"Hepatocyte mitochondria-derived danger signals directly activate hepatic stellate cells and drive progression of liver fibrosis","volume":"11","author":"An","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.heliyon.2024.e30387_bib88","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1016\/j.cell.2018.09.053","article-title":"Obesity drives STAT-1-dependent NASH and STAT-3-dependent HCC","volume":"175","author":"Grohmann","year":"2018","journal-title":"Cell."},{"key":"10.1016\/j.heliyon.2024.e30387_bib89","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1016\/j.jhep.2020.07.030","article-title":"Targeting NFATc4 attenuates non-alcoholic steatohepatitis in mice","volume":"73","author":"Du","year":"2020","journal-title":"J. Hepatol."},{"key":"10.1016\/j.heliyon.2024.e30387_bib90","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1002\/hep.31582","article-title":"Osteopontin takes center stage in chronic liver disease","volume":"73","author":"Song","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.heliyon.2024.e30387_bib91","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1038\/s41374-020-0425-4","article-title":"SPOCK1 overexpression induced by platelet-derived growth factor-BB promotes hepatic stellate cell activation and liver fibrosis through the integrin \u03b15\u03b21\/PI3K\/Akt signaling pathway","volume":"100","author":"Du","year":"2020","journal-title":"Lab. Investig."},{"key":"10.1016\/j.heliyon.2024.e30387_bib92","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nature26138","article-title":"Hepatocyte-secreted DPP4 in obesity promotes adipose inflammation and insulin resistance","volume":"555","author":"Ghorpade","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.heliyon.2024.e30387_bib93","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.91809","article-title":"\u03b2-Klotho deficiency protects against obesity through a crosstalk between liver, microbiota, and brown adipose tissue","volume":"2","author":"Somm","year":"2017","journal-title":"JCI Insight"},{"key":"10.1016\/j.heliyon.2024.e30387_bib94","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-017-02074-2","article-title":"Hepatic protein tyrosine phosphatase receptor gamma links obesity-induced inflammation to insulin resistance","volume":"8","author":"Brenachot","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.heliyon.2024.e30387_bib95","doi-asserted-by":"crossref","first-page":"4449","DOI":"10.1172\/JCI96324","article-title":"Hepatic neuregulin 4 signaling defines an endocrine checkpoint for steatosis-to-NASH progression","volume":"127","author":"Guo","year":"2017","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.heliyon.2024.e30387_bib96","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-019-09524-z","article-title":"Hepatocyte-specific loss of GPS2 in mice reduces non-alcoholic steatohepatitis via activation of PPAR\u03b1","volume":"10","author":"Liang","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.heliyon.2024.e30387_bib97","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.tig.2020.03.003","article-title":"The epigenetic drug discovery landscape for metabolic-associated fatty liver disease","volume":"36","author":"Bayoumi","year":"2020","journal-title":"Trends Genet."},{"key":"10.1016\/j.heliyon.2024.e30387_bib98","article-title":"Epigenetic regulation of hepatic lipid metabolism by DNA methylation","author":"Wang","year":"2023","journal-title":"Adv. Sci."},{"key":"10.1016\/j.heliyon.2024.e30387_bib99","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1080\/21655979.2021.2014387","article-title":"DNA methylation across the tree of life, from micro to macro-organism","volume":"13","author":"Nasrullah","year":"2022","journal-title":"Bioengineered"},{"key":"10.1016\/j.heliyon.2024.e30387_bib100","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13072-023-00478-7","article-title":"Dynamic changes in whole genome DNA methylation, chromatin and gene expression during mouse lens differentiation","volume":"16","author":"Chang","year":"2023","journal-title":"Epigenet. Chromatin"},{"key":"10.1016\/j.heliyon.2024.e30387_bib101","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241914482","article-title":"MicroRNAs and nonalcoholic steatohepatitis: a review","volume":"24","author":"Morishita","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.heliyon.2024.e30387_bib102","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1136\/gutjnl-2017-315691","article-title":"Non-alcoholic steatohepatitis pathogenesis: sublethal hepatocyte injury as a driver of liver inflammation","volume":"67","author":"Ibrahim","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.heliyon.2024.e30387_bib103","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/s41575-018-0065-y","article-title":"Apoptosis and necroptosis in the liver: a matter of life and death","volume":"15","author":"Schwabe","year":"2018","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.heliyon.2024.e30387_bib104","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/nm.4290","article-title":"Targeting CASP8 and FADD-like apoptosis regulator ameliorates nonalcoholic steatohepatitis in mice and nonhuman primates","volume":"23","author":"Wang","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.heliyon.2024.e30387_bib105","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/nm.4453","article-title":"The deubiquitinating enzyme TNFAIP3 mediates inactivation of hepatic ASK1 and ameliorates nonalcoholic steatohepatitis","volume":"24","author":"Zhang","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.heliyon.2024.e30387_bib106","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1002\/hep4.1069","article-title":"TRAIL deletion prevents liver inflammation but not adipose tissue inflammation during murine diet\u2010induced obesity","volume":"1","author":"Hirsova","year":"2017","journal-title":"Hepatol. Commun."},{"key":"10.1016\/j.heliyon.2024.e30387_bib107","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.cell.2018.08.020","article-title":"ER stress drives lipogenesis and steatohepatitis via caspase-2 activation of S1P","volume":"175","author":"Kim","year":"2018","journal-title":"Cell."},{"key":"10.1016\/j.heliyon.2024.e30387_bib108","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/liv.14362","article-title":"Natural history of NASH and HCC","volume":"40","author":"Negro","year":"2020","journal-title":"Liver Int."},{"key":"10.1016\/j.heliyon.2024.e30387_bib109","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.cgh.2015.07.019","article-title":"Hepatocellular carcinoma in the absence of cirrhosis in United States veterans is associated with nonalcoholic fatty liver disease","volume":"14","author":"Mittal","year":"2016","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.heliyon.2024.e30387_bib110","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1002\/hep.28368","article-title":"Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: a multicenter prospective study","volume":"63","author":"Piscaglia","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.heliyon.2024.e30387_bib111","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1080\/03007995.2019.1683817","article-title":"Hepatocellular carcinoma in non-alcohol fatty liver disease\u2013changing trends and specific challenges","volume":"36","author":"Berkan-Kawi\u0144ska","year":"2020","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.heliyon.2024.e30387_bib112","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1016\/j.cgh.2020.08.065","article-title":"A novel blood-based panel of methylated DNA and protein markers for detection of early-stage hepatocellular carcinoma","volume":"19","author":"Chalasani","year":"2021","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.heliyon.2024.e30387_bib113","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11892-021-01377-5","article-title":"Genetic contribution to non-alcoholic fatty liver disease and prognostic implications","volume":"21","author":"Martin","year":"2021","journal-title":"Curr. Diab. Rep."},{"key":"10.1016\/j.heliyon.2024.e30387_bib114","doi-asserted-by":"crossref","DOI":"10.3389\/fnut.2023.1101341","article-title":"The I148M PNPLA3 variant mitigates niacin beneficial effects: how the genetic screening in non-alcoholic fatty liver disease patients gains value","volume":"10","author":"Paolini","year":"2023","journal-title":"Front. Nutr."},{"key":"10.1016\/j.heliyon.2024.e30387_bib115","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/S0140-6736(14)60892-8","article-title":"Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5\u00b7 24 million UK adults","volume":"384","author":"Bhaskaran","year":"2014","journal-title":"Lancet."},{"key":"10.1016\/j.heliyon.2024.e30387_bib116","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.jceh.2019.11.004","article-title":"Diabetes and hepatocellular carcinoma: incidence trends and impact of liver disease etiology","volume":"10","author":"Doycheva","year":"2020","journal-title":"J. Clin. Exp. Hepatol."},{"key":"10.1016\/j.heliyon.2024.e30387_bib117","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1002\/hep.30858","article-title":"Diabetes is associated with increased risk of hepatocellular carcinoma in patients with cirrhosis from nonalcoholic fatty liver disease","volume":"71","author":"Yang","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.heliyon.2024.e30387_bib118","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/9547613","article-title":"Role of oxidative stress in pathophysiology of nonalcoholic fatty liver disease","volume":"2018","author":"Masarone","year":"2018","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.heliyon.2024.e30387_bib119","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1080\/10715762.2019.1624743","article-title":"Effects of GST null genotypes on individual susceptibility to atherosclerotic cardiovascular diseases: a meta-analysis","volume":"54","author":"Li","year":"2020","journal-title":"Free Radic. Res."},{"key":"10.1016\/j.heliyon.2024.e30387_bib120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-018-06931-6","article-title":"Dietary cholesterol promotes steatohepatitis related hepatocellular carcinoma through dysregulated metabolism and calcium signaling","volume":"9","author":"Liang","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.heliyon.2024.e30387_bib121","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aap9840","article-title":"Squalene epoxidase drives NAFLD-induced hepatocellular carcinoma and is a pharmaceutical target","volume":"10","author":"Liu","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.heliyon.2024.e30387_bib122","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41575-018-0089-3","article-title":"Metabolic aspects in NAFLD, NASH and hepatocellular carcinoma: the role of PGC1 coactivators","volume":"16","author":"Piccinin","year":"2019","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.heliyon.2024.e30387_bib123","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1130380","article-title":"AATF inhibition exerts antiangiogenic effects against human hepatocellular carcinoma","volume":"13","author":"Suresh","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.heliyon.2024.e30387_bib124","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41419-020-2283-9","article-title":"Hepatocyte apoptosis is tumor promoting in murine nonalcoholic steatohepatitis","volume":"11","author":"Hirsova","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.heliyon.2024.e30387_bib125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-018-07338-z","article-title":"Autophagy is a gatekeeper of hepatic differentiation and carcinogenesis by controlling the degradation of Yap","volume":"9","author":"Lee","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.heliyon.2024.e30387_bib126","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.ccr.2014.08.007","article-title":"Endoplasmic reticulum stress: at the crossroads of inflammation and metabolism in hepatocellular carcinoma development","volume":"26","author":"Maurel","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.heliyon.2024.e30387_bib127","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.3389\/fphar.2018.01428","article-title":"The role of Nrf2 in liver disease: novel molecular mechanisms and therapeutic approaches","volume":"9","author":"Xu","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.heliyon.2024.e30387_bib128","article-title":"Association between gut microbiota and hepatocellular carcinoma from 2011 to 2022: bibliometric analysis and global trends","volume":"13","author":"Chen","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.heliyon.2024.e30387_bib129","doi-asserted-by":"crossref","DOI":"10.3390\/ijms231911689","article-title":"Current research on the pathogenesis of NAFLD\/NASH and the gut\u2013liver Axis: gut microbiota, dysbiosis, and leaky-gut syndrome","volume":"23","author":"Kobayashi","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.heliyon.2024.e30387_bib130","doi-asserted-by":"crossref","DOI":"10.14309\/ctg.0000000000000131","article-title":"Altered microbiota diversity and bile acid signaling in cirrhotic and noncirrhotic NASH-HCC","volume":"11","author":"Sydor","year":"2020","journal-title":"Clin. Transl. Gastroenterol."},{"key":"10.1016\/j.heliyon.2024.e30387_bib131","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.livres.2017.11.005","article-title":"Gut microbiota, fatty liver disease, and hepatocellular carcinoma","volume":"2","author":"Chu","year":"2018","journal-title":"Liver Res"},{"key":"10.1016\/j.heliyon.2024.e30387_bib132","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/nature12347","article-title":"Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome","volume":"499","author":"Yoshimoto","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.heliyon.2024.e30387_bib133","doi-asserted-by":"crossref","DOI":"10.1126\/science.aan5931","article-title":"Gut microbiome\u2013mediated bile acid metabolism regulates liver cancer via NKT cells","volume":"360","author":"Ma","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.heliyon.2024.e30387_bib134","doi-asserted-by":"crossref","DOI":"10.21037\/atm.2020.02.21","article-title":"Palmitic acid stimulates NLRP3 inflammasome activation through TLR4-NF-\u03baB signal pathway in hepatic stellate cells","volume":"8","author":"Dong","year":"2020","journal-title":"Ann. Transl. Med."},{"issue":"11","key":"10.1016\/j.heliyon.2024.e30387_bib135","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1056\/NEJMoa2304286","article-title":"Randomized, controlled trial of the FGF21 analogue pegozafermin in NASH","volume":"398","author":"Loomba","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.heliyon.2024.e30387_bib136","first-page":"371","article-title":"Update on clinical trials for nonalcoholic steatohepatitis","volume":"19","author":"Nathani","year":"2023","journal-title":"Gastroenterol. Hepatol."},{"key":"10.1016\/j.heliyon.2024.e30387_bib137","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.heliyon.2024.e30387_bib138","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.1087260","article-title":"Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD)","volume":"13","author":"Rong","year":"2023","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.heliyon.2024.e30387_bib139","series-title":"Non-Alcoholic Fatty Liver Disease","author":"Uk","year":"2016"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e30387_bib140","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jhep.2023.10.015","article-title":"Artificial intelligence-assisted digital pathology for non-alcoholic steatohepatitis: current status and future directions","volume":"80","author":"Ratziu","year":"2024","journal-title":"J. Hepatol."},{"key":"10.1016\/j.heliyon.2024.e30387_bib141","doi-asserted-by":"crossref","first-page":"S493","DOI":"10.1016\/S0168-8278(22)01317-4","article-title":"Magnetic resonance elastography (MRE) demonstrate the strongest correlation with digital pathology and NASH CRN fibrosis assessments, compared to transient elastography and other assessed non-invasive tests (NITs)","volume":"77","author":"Martic","year":"2022","journal-title":"J. Hepatol."}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024064181?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024064181?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T01:25:59Z","timestamp":1758677159000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844024064181"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":141,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S2405844024064181"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e30387","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"From NAFLD to NASH: Understanding the spectrum of non-alcoholic liver diseases and their consequences","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e30387","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e30387"}}